Sagent Pharmaceuticals, Inc. Securities Litigation
On or around 10/05/2016 (Notice of voluntarily dismissal)
Filing Date: August 09, 2016
According to a law firm's press release, on July 10, 2016, Sagent’s Board of Directors (the “Board”) caused Sagent to enter into an agreement and plan of merger with Nichi-Iko Pharmaceutical Co., Ltd. and its subsidiary Shepard Vision, Inc. (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, stockholders of Sagent will receive $21.75 per share in cash. The Complaint alleges that on August 1, 2016, Defendants issued materially incomplete and misleading disclosures in the Solicitation/Recommendation Statement filed on Schedule 14D-9 (the “Solicitation Statement”) filed with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction. According to the Complaint, the Solicitation Statement is deficient and misleading in that it fails to provide adequate disclosure of all material information related to the Proposed Transaction.
This case was voluntarily dismissed on October 5, 2016.
Company & Securities Information
Defendant: Sagent Pharmaceuticals, Inc.
Industry: Major Drugs
Headquarters: United States
Ticker Symbol: SGNT
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jeffrey Karbash, et al. v. Sagent Pharmaceuticals, Inc., et al.